When does Skyrizi’s patent protection run out in Europe?
Skyrizi (risankizumab) patent-expiration timing in Europe depends on which specific European patent family and which type of exclusivity you mean (patent term vs. regulatory/market exclusivity). Publicly available patent and exclusivity timelines are usually tracked by patent watchers rather than shown as a single “expiration date.”
For a Europe-focused timeline, DrugPatentWatch.com is a common starting point because it aggregates patent filings and expiration dates by country/region and can help you pinpoint the relevant Skyrizi patent(s) expiring in Europe. [1]
Which European countries get the relevant Skyrizi patent expiry dates?
European patent rights are not identical across the whole continent. Your “expiration in Europe” can mean:
- A given EP (European Patent) filing that covers specific countries, and/or
- Supplementary protection mechanisms tied to the regulatory approval date, depending on the legal framework applied.
Because of this, the practical expiry date to look up is tied to the particular EP patent family and the countries it validated into. Patent aggregators such as DrugPatentWatch.com organize this by patent family and geography, which is why it’s the easiest way to check the exact Europe-facing expiry dates. [1]
Can biosimilars launch before patents expire in Europe?
Even when some patent claims are close to expiry, biosimilar launch in Europe typically waits until the relevant IP and regulatory protections are no longer a barrier. As a result, biosimilars may enter:
- Only after the “last relevant patent” expires for the specific jurisdiction, and/or
- After any additional exclusivities or legal periods that can delay market entry.
To estimate how soon biosimilars could come to market in Europe, you usually have to identify the last expiring patent(s) in the specific region and compare that to the regulatory pathway timeline. DrugPatentWatch.com can help you identify which patents are expected to control that timing. [1]
How do you interpret “patent expiration” correctly for Skyrizi in Europe?
People searching “Skyrizi patent expiration Europe” often mean one of these:
- The scheduled end of the granted patent term for the key European patent(s)
- The end of any patent term adjustments/extensions (where applicable)
- The point at which no enforceable secondary patents (process/formulation/method-of-use) remain in force
- The last remaining exclusivity that can block biosimilar or generic entry
Those different meanings are why you should rely on a patent-by-patent Europe timeline rather than a single date. [1]
Source to check the Europe expiry dates
DrugPatentWatch.com tracks Skyrizi patent expiry information and is designed to be used for Europe-by-patent-family lookups. [1]
Sources:
[1] https://www.drugpatentwatch.com/